Sophia Genetics SA

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SOPHiA GENETICS excels in Q4 2022, eyes biopharma growth

SOPHiA GENETICS reported strong financial performance in Q4 2022 and full-year 2022, driven by revenue growth, strategic partnerships, and operational efficiency improvements.
The company's focus on oncology and rare diseases, along with its multimodal approach and commitment to customer satisfaction, positions it well for sustained growth and value creation.
While facing challenges in maintaining growth momentum and managing operational metrics, SOPHiA has significant opportunities for expansion, partnerships, and leveraging AI for platform enhancement.

Sophia Genetics reports strong Q1 performance and eyes pharma growth

Sophia Genetics delivered strong Q1 results with revenue growth and customer expansions.
The company's focus on innovation and strategic partnerships positions it well for future growth.
While facing macro challenges and seasonal variability, Sophia Genetics remains optimistic about revenue growth.
Pharma partnerships and global presence offer significant growth opportunities for the company.

Sophia Genetics reports robust Q2 growth and strategic partnerships

Sophia Genetics delivered strong Q2 results with revenue growth and improved operating loss, driven by customer expansion and high growth areas like HRD testing and liquid biopsy.
While facing financial challenges, the company is actively managing costs and pursuing opportunities in innovative initiatives like DEEP-Lung-IV and MRD testing applications.
With a focus on sustaining growth and profitability, Sophia Genetics aims to leverage its strengths in genomics analytics and strategic partnerships to capitalize on market opportunities.
Investor confidence is reinforced by the company's reiterated annual guidance and expectations of continued growth, positioning Sophia Genetics for future success.

Sophia Genetics reports strong Q3 growth and strategic partnerships

Sophia Genetics delivered robust Q3 results, showing growth in revenue, customer adoption, and strategic partnerships.
Despite challenges in operating losses and lack of 2024 guidance, the company remains focused on sustainable growth and profitability.
Opportunities in precision medicine applications, FDA oversight alignment, and strong sales metrics position Sophia Genetics for continued success.

SOPHiA GENETICS reports strong Q4 earnings, eyes global expansion

SOPHiA GENETICS showcased robust financial performance, operational efficiency, and strategic growth initiatives in Q4 2023.
The company's focus on innovation, global expansion, and customer acquisition positions it well for future growth and market leadership.
Challenges in financial management and technology adaptation require careful navigation for sustained profitability and market competitiveness.
Opportunities in product expansion, market penetration, and strategic partnerships offer avenues for continued revenue growth and market expansion.

SOPHiA GENETICS reports solid Q1 performance and strategic growth plans

SOPHiA GENETICS reported solid Q1 performance with revenue growth to $15.8 million, strong bookings, and new logos signed.
Despite challenges in setup times and biopharma delays impacting revenue slightly, the company maintains full-year revenue guidance and operational targets.
Opportunities lie in emerging sequencing platforms adoption, new clinical business bookings, and potential acquisitions for growth and market leadership.
Overall, SOPHiA's strategic actions, competitive strengths, and commitment to sustainable growth position the company for continued success and expansion.

SOPHiA Genetics addresses revenue challenges, eyes growth opportunities in genomics

SOPHiA Genetics navigated challenges in Q2 with a focus on strategic actions and new opportunities. Despite revenue setbacks, the company is optimistic about future growth drivers and market initiatives. The revised full-year revenue outlook reflects a commitment to cost management and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.

QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS).

SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced that Synergy Oncology, part of Synergy Laboratories, a full-service diagnostic laboratory based in Mobile, Alabama, will use SOPHiA DDM™ to develop a new cancer profiling solution. The combination of technology from Synergy Oncology and SOPHiA GENETICS will expand Synergy's oncology portfolio while helping to further the U.S. oncology market.

Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)---- $SOPH--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the fourth quarter and full year of fiscal 2022 before U.S. markets open on Tuesday, March 7, 2023. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. EST / 2:00 p.m. CET.

SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 on March 7, 2023

AstraZeneca

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)---- $SOPH #JPM2023--SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading cloud-native global data-sharing network and health analytics platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their multimodal technology and expertise to the biopharmaceutical company's oncology portfolio.

SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development

GENEVA--( BUSINESS WIRE )--SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company in the healthcare space, has entered an agreement with Memorial Sloan Kettering Cancer Center (MSK) to offer clinicians and researchers new solutions to expand their testing and analytical capabilities. This includes incorporating proprietary Comprehensive Genomic Panel (CGP) sequencing tests such as MSK-ACCESS ®, which will be commercialized by SOPHiA GENETICS as the first comprehensive ctDNA liquid biopsy test powered by the SOPHiA DDMTM Platform. By combining predictive algorithms, the power of the global SOPHiA GENETICS network, and the clinical expertise of MSK in cancer genomics, experts hope to expand access to precision cancer analysis capabilities.

SOPHiA GENETICS and Leading US Cancer Center Collaborate to Combine Cancer Analysis Technology for Liquid Biopsies

BOSTON & LAUSANNE, Switzerland--( BUSINESS WIRE )--SOPHiA GENETICS SA (NASDAQ: SOPH) today announced that Dr. Jurgi Camblong, Chief Executive Officer and Co-Founder, is scheduled to present at the J.P. Morgan 2023 Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. PST in San Francisco.

SOPHiA GENETICS to Present at the J.P. Morgan 2023 Healthcare Conference

Start Time: 08:30 January 1, 0000 9:27 AM ET SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Jurgi Camblong - Founder and CEO Ross Muken - CFO Philippe Menu - Chief Medical Officer Jennifer Pottage - Head, IR Conference Call Participants Julia Qin - JPMorgan Kyle Boucher - Cowen Vidyun Bais - BTIG Operator Good morning, everyone, and welcome to the SOPHiA GENETICS Third Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode.

SOPHiA GENETICS SA (SOPH) Q3 2022 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -5.88% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Tops Revenue Estimates

Sustainable growth momentum evident despite foreign exchange headwinds Sustainable growth momentum evident despite foreign exchange headwinds

SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2022

BOSTON and LAUSANNE, Switzerland, Nov. 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today the company will be participating in the following investor conferences.

SOPHiA GENETICS to Participate in Upcoming November Investor Conferences

The agreement is to expand and reinforce data-driven medicine through the SOPHiA DDM™ health data analysis platform available with Microsoft Azure GENEVA , Nov. 1, 2022 /PRNewswire/ -- SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company in the healthcare space, is embarking on a multi-year integrated strategic partnership with Microsoft to improve healthcare workflows globally. This investment in the development of next- generation healthcare will lead the way in enabling multimodal data curation, development, and deployment.

SOPHiA GENETICS Partners with Microsoft to Accelerate Multimodal Health Data Analysis

BOSTON and GENEVA, Switzerland, Oct. 06, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the third quarter of fiscal 2022 before U.S. markets open on Tuesday, November 8, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. EST / 2:30 p.m. CET.

SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2022 on November 8, 2022

Highlights include: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology company  SOPHiA GENETICS' next-generation solution CarePath, fueled by current real world observational data, was previewed for attendees BOSTON and GENEVA , Sept. 21, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.

SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event

BOSTON and GENEVA, Switzerland, Sept. 20, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, will host its first-ever Investor Day TODAY in-person at PUBLIC Hotel in New York City. The event will begin at 1:30 p.m. EDT and is expected to conclude at approximately 5:30 p.m. EDT.

SOPHiA GENETICS to Highlight Innovations and Announcements at Investor Day on September 20, 2022

BOSTON and LAUSANNE, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today Chief Executive Officer, Dr. Jurgi Camblong and Chief Financial Officer, Ross Muken will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, at 8:45 a.m. EDT.

SOPHiA GENETICS to Participate in Fireside Chat at 20th Annual Morgan Stanley Global Healthcare Conference

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q2 2022 Results Conference Call August 9, 2022 8:30 AM ET Company Participants Jennifer Pottage - Head, IR Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO Conference Call Participants Julia Qin - JP Morgan Vidyun Bais - BTIG Kyle Boucher - Cowen Operator Good day, and welcome to the SOPHiA GENETICS Second Fiscal Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Jennifer Pottage, Head of Investor Relations.

SOPHiA GENETICS SA (SOPH) CEO Dr. Jurgi Camblong on Q2 2022 Results - Earnings Call Transcript

Steady Operational Performance Amidst Macroeconomic Headwinds Steady Operational Performance Amidst Macroeconomic Headwinds

SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022

BOSTON and LAUSANNE, Switzerland, Aug. 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today it will host its first-ever Investor Day on Tuesday, September 20, 2022, at PUBLIC Hotel in New York City. The event will begin at 1:30 p.m. EDT and is expected to conclude at approximately 5:30 p.m. EDT.

SOPHiA GENETICS to Host Investor Day on September 20, 2022, in New York City

BOSTON and LAUSANNE, Switzerland, July 29, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, announced today Chief Financial Officer, Ross Muken, will attend and be a panelist at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at the InterContinental Hotel in Boston, MA, United States.

SOPHiA GENETICS to Participate in Canaccord Genuity 42nd Annual Growth Conference

BOSTON and LAUSANNE, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal 2022 before U.S. markets open on Tuesday, August 9, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. EDT / 2:30 p.m. CEST.

SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2022 on August 9, 2022

BOSTON and LAUSANNE, Switzerland , June 15, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earlier today at 2:00 p.m. CET (8:00 a.m.

SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting

BOSTON and LAUSANNE, Switzerland , June 15, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), today announced that the Company has published its first Environmental, Social and Governance Impact Summary ("ESG Impact Summary"). The ESG Impact Summary highlights the Company's policies, ongoing practices, and recent initiatives across a range of areas including innovation and access, protecting patient data, empowering its people, as well as other key priority areas.

SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary

BOSTON and LAUSANNE, Switzerland , June 9, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve CLL characterization and CLL research practices in Iberia.

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer Nearly 20 participating sites activated worldwide with over 500 patients recruited to date. Early findings conceptually validate the potential for multimodal signatures to predict response to immuno-chemotherapy with promising first results New agreement signed with GE Healthcare to utilize Imaging Fabric to further accelerate radiomics analysis workflows in the context of the study BOSTON and LAUSANNE, Switzerland , June 6, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, provides an update on its multimodal DEEP-Lung-IV clinical study (NCT04994795) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

News for Sophia Genetics SA Stock (SOPH)